T-CURX bolsters leadership team to advance CAR-T cell therapies

6 June 2023

German CAR-T cell therapy specialist T-CURX has announced two appointments to its senior leadership team.

Michael Hudecek has been named chief medical officer, while Karl Schumacher has become chief clinical officer.

"Michael and Karl will accelerate our clinical trial activities for developing next-generation CAR-T therapies"Professor Hudecek is one of the scientific co-founders of T-CURX and is part of the company’s scientific advisory board. He will now also join the management team as part-time CMO.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK